Page 112 - TD-4-2

Tumor Discovery DLBCL in the splenic hilar lymph node

doi: 10.1186/s12957-024-03509-z 15. Boyer DF, McKelvie PA, de Leval L, et al. Fibrin-associated
EBV-positive large B-cell lymphoma: An indolent neoplasm
12. Abdulbaki R, Tizro P, Nava VE, da Silva MG, Ascensão JL. with features distinct from diffuse large B-cell lymphoma
Low-grade primary splenic CD10-positive small associated with chronic inflammation. Am J Surg Pathol.
B-cell lymphoma/follicular lymphoma. Curr Oncol. 2017;41:299-312.
2021;28(6):4821-4831.
doi: 10.1097/PAS.0000000000000775
doi: 10.3390/curroncol28060407
16. Bairey O, Shvidel L, Perry C, et al. Characteristics of primary
13. Samuel B, Nalbandyan K, Benharroch D, Levi I. Splenic splenic diffuse large B-cell lymphoma and role of splenectomy
micronodular T-cell/histiocyte-rich large B-cell lymphoma: in improving survival. Cancer. 2015;121:2909-2916.
The corticosteroid pretreatment hypothesis. Acta Haematol.
2022;145(3):310-317. doi: 10.1002/cncr.29487
doi: 10.1159/000520791 17. Persky DO, Li H, Stephens DM, et al. Positron emission
tomography-directed therapy for patients with limited-
14. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab stage diffuse large B-cell lymphoma: Results of intergroup
vedotin in previously untreated diffuse large B-cell national clinical trials network study S1001. J Clin Oncol.
lymphoma. N Engl J Med. 2022;386(4):351-363. 2020;38(26):3003-3011.
doi: 10.1056/NEJMoa2115304 doi: 10.1200/JCO.20.00999

Volume 4 Issue 2 (2025) 104 doi: 10.36922/td.6742